Ipsen S.A. (EPA: IPN)
France
· Delayed Price · Currency is EUR 109.70
+1.00 (0.92%)
Aug 30, 2024, 5:35 PM CET
Ipsen Revenue
Ipsen had revenue of 1.27B EUR in the half year ending June 30, 2024, with 42.65% growth. This brings the company's revenue in the last twelve months to 2.50B, up 17.20% year-over-year. In the year 2023, Ipsen had annual revenue of 2.31B with 18.88% growth.
Revenue (ttm)
2.50B
Revenue Growth
+17.20%
P/S Ratio
2.64
Revenue / Employee
645.09K
Employees
5,325
Market Cap
9.06B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 2.31B | 367.00M | 18.88% |
| Dec 31, 2022 | 1.94B | 361.00M | 22.80% |
| Dec 31, 2021 | 1.58B | 160.00M | 11.24% |
| Dec 31, 2020 | 1.42B | -147.00M | -9.36% |
| Dec 31, 2019 | 1.57B | 243.00M | 18.31% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| LVMH Moët Hennessy - Louis Vuitton, Société Européenne | 85.59B |
| Hermès International Société en commandite par actions | 14.23B |
| L'Oréal S.A. | 42.73B |
| Schneider Electric S.E. | 36.44B |
| Christian Dior SE | 85.59B |
| EssilorLuxottica Société anonyme | 25.83B |
| L'Air Liquide S.A. | 27.01B |
| AXA SA | 90.56B |
Ipsen News
- 5 weeks ago - Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024) - GlobeNewsWire
- 3 months ago - Annual General Meeting of Ipsen S.A. held on 28 May 2024 - GlobeNewsWire
- 3 months ago - Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.'s Annual General Meeting on 28 May 2024 - GlobeNewsWire
- 4 months ago - Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting - GlobeNewsWire
- 4 months ago - Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance - GlobeNewsWire
- 7 months ago - Ipsen S.A. publishes its 2023 Consolidated Financial Statements - GlobeNewsWire
- 1 year ago - US FDA approves Ipsen's rare bone disorder drug - Reuters
- 1 year ago - US FDA approves Ipsen's SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva - GlobeNewsWire